By Peter McLaren-Kennedy •
Published: 04 Nov 2022 • 7:54
COVID-19 infections. Credit: Alina Troeva/Shutterstock.com.
The case of the 59-year-old patient was published in the journal Clinical Infectious Diseases on Thursday, November 4 by medical staff from the Guy’s and St Thomas’ Hospitals.
The unnamed patient, whose immune system was compromised due to a kidney transplant, tested positive in December 2020.
Unable to clear the infection and continuing to test positive until January 2022, genetic analysis determined that he had an early variant of the original strain that led to the world being shut down.
Once they had identified the strain, they use the same cocktail of drugs that had “miraculously” cured the American President Donald Trump, Regeneron.
But the cure did not work for everyone with another patient in a similar situation and who had tested positive for 505 days, died after being administered the same cocktail of drugs.
Both are said to have caught the virus but were never re-infected, a situation different to those with long COVID-19 where the symptoms continue but the virus is no longer present.
The team have called for more research into antibody treatments and for the approval of a new drug, Evusheld that is said to be more effective in dealing with the virus.
Speaking to Sky News Dr Luke Blagdon Snell said: “Some new variants of the virus are resistant to all the antibody treatments available in the UK and Europe.
“Some people with weakened immune systems are still at risk of severe illness and becoming persistently infected. We are still working to understand the best way to protect and treat them.”
Cases remain of people who have been infected by the virus for more than a year, most of whom have suffered serious medical issues. The news that a Brit has been cured after 411 days of COVID-19 will give them and medical professionals some hope.
Thank you for taking the time to read this article, do remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and remember, you can also follow us on Facebook and Instagram.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our
Originally from South Africa, Peter is based on the Costa Blanca and is a web reporter for the Euro Weekly News covering international and Spanish national news.
Got a news story you want to share? Then get in touch at email@example.com.
They should have given him Ivermectin as soon as he tested positive. The only reason that ivermectin has not been widely used is that it is a generic drug that can be safely used while being cheap. As it is generic it does not make money for the company who origianlly developed it, Merck.
Even more importantly, if governments and healthcare systems had used ivermectin, the vaccines would not have been given EUA (Emergency Use Authorisation) and the pharma companies would not have been able to use or profit from the vaccines until they had been fully tested, which takes years – this is because Emergency Use Authorisation can only be given if there is no other effective treatment for a particular illness. Basically what I am saying is that Ivermectin was not used as there would have been no profits as no vaccines would have been able to be used under EUA.
covid does not exist…..The only place it exists is inside the minds of zionists
What planet are you living on, Zionists are people who believe in the development of Israel as a Jewish Nation. So how come if Covid is purely in their minds 4.5 million have had Covid in Israel and sadly 11000 have died from it.
Covid 19 was a secondary use for the unlicensed injections, people are therfore urged to do their own research to discover their primary use, we also do not see any government puppits falling foul of the after effects of the jabs, that is the salient point if you get my drift!
Comments are closed.
Download our media pack in either English or Spanish.